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Abstract: 
Introduction:  A screening program has been implemented in SA with intervals of 10 years 
after a normal cytological result. There are no studies which evaluate repeat screening at a 
shorter interval in SA.  
Aim: This study aims to find the incidence of cytological abnormalities on a repeat test after a 
report of normal cytology or an inadequate pap smear. The factors associated with an 
abnormal cytology on repeat testing will also be explored. 
Methods: This is a secondary data analysis of the information obtained in a trial investigating 
the use of the diaphragm in the prevention of HIV infection between 2004 and 2006. Women 
were offered a Papanicolaou (Pap) smear at the enrolment visit and again at the end of the 
trial. The incidence of abnormal cytology after a normal or inadequate cytology was 
obtained. Demographic factors, history, clinical findings and tests for STI were compared 
amongst women with a normal and abnormal Pap smear on repeat testing after a normal 
Pap smear.  
Results:  The incidence of cytological abnormalities was 6.48 % per annum in women with a 
previously normal Pap and 11.71% per annum in women with an inadequate smear result. 
(Log rank test for difference significant (p=0.03)). The incidence of cytological abnormalities 
in women with either an inadequate Pap smear or a normal Pap smear was 7.33%. However, 
the incidence of a high grade lesion was less than 0.5%. Factors associated with abnormal 
cytology in the multivariate analysis were a history of ectopic pregnancy [OR=9.25 (CI-1.78-
48.03), p=0.01], number of male partners [0R=1.12 (CI-1.03-1.22),p=0.01],  number of times 
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a women was treated for an STI [OR=6.59 (1.54-28.19), p=0.01], history of vaginal discharge 
[OR=13.95 (1.18-164.47), p=0.00], and HIV infection [OR=6.58 (1.14-38.16),p=0.04]. 
Conclusion: The incidence of significant cervical lesions is low, but it would be prudent to 
continue to repeat those Pap smears that are found to be inadequate with the present 
interval of 10 years. In women with a normal Pap smear, a repeat Pap smear after 1-2 years 
should only be performed if clinically indicated.   
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Chapter 1: Background and Literature Review: 
Background: 
Cancer of the cervix remains a huge problem in South Africa (SA), it is the most common 
cancer in Black women with an age standardized risk (ASR) of 30.56 per 100 000 in 2001(2). 
The lifetime risk of a woman developing cancer is 1 in 8 (2001). Cancer of the breast (1 in 29) 
and cancer of the cervix (1 in 35) are the two leading cancers followed by uterine, colorectal 
and oesophageal cancer. There were 4817 cases  of cervical cancer in 2001 in SA, with a 
quarter occurring in women between the ages of 40 and 50 years(2). Approximately 80% of 
the cervical malignancies now occur in the developing world(3). 
 Population based screening and treatment programs of pre-malignant lesions of the 
cervix has significantly reduced the morbidity and mortality associated with cervical cancer, 
with reductions in death of between 45% and 80%(4-6). Screening, using Papanicolaou 
smears (multichromatic staining of exfoliated cervical cells- hereinafter referred to as “Pap 
smear”) was first shown to reduce the incidence rate and death rate from cervical cancer in 
British Columbia(7). Cervical cancer screening was advocated in several countries although 
comprehensive programs were only introduced in a few countries like Iceland, Finland and 
Northeast Scotland in the 1960’s and 1970’s.  
Systematic screening was only implemented in the United Kingdom (UK) in 1988. This 
program involved every woman between the ages of 20 and 64 being called and recalled 
every 3 to 5 years. This has resulted in a reduction of the death rate by 50% since 1988(5). It 
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is estimated that 2000 lives a year are saved. Population coverage has been one of main 
reasons for the success of the UK screening program.  The coverage in the UK had reached 
80.6% by 2004. 
The SA government introduced the  National Screening program for the prevention of 
Cervical Cancer(8), using the WHO recommendation for middle income countries. The WHO 
recommendation, which was that when 80% of women have been screened, the interval 
should be between 5 and 10 years, as resources permit(9). In SA an interval of 10 years has 
been advocated for the present. The South African program aims at achieving a wide 
coverage and in earlier presentation. Screening intervals of more than 5 years have never 
been tested in any program. 
The challenges in cervical cancer prevention are unlikely to be the same in highly 
resourced settings and in countries like SA which have a high disease burden(10, 11).  
Prevention of cancer of the cervix is dependent on integration of screening, referral, 
diagnosis, treatment, and follow-up of women with pre-malignant lesions of the cervix. Every 
aspect of the prevention program has to be equally pursued to be successful. 
It is important to know the incidence and prevalence of cervical abnormalities in order to 
provide treatment for screened women as well as for making decisions regarding repeat 
screening.  
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Problem Statement: 
 Even though the incidence of cervical cancer has been reduced in countries with 
both opportunistic and systematic screening, cervical cancer continues to be a health 
problem(5). Ten percent of cervical cancer cases occur in women who have been screened, 
but all of these were where the screening was at least 5 years ago and more than 50% occur 
in women who have never been screened(11). There have been no prospective studies 
comparing the outcomes of screening at different intervals in any population. 
In SA, the cancer prevention program is aimed at getting wide coverage (screening 
70% of women in 10 years). Women will be offered three pap smears in a lifetime starting at 
the age of 30, however if the first  pap smear is after the age of 55 and is normal only one 
pap smear will be performed. Women in whom the cytology is reported as inadequate will 
be re-screened. Women with any gynaecological complaint should receive a smear as part of 
their gynaecological examination irrespective of their screening history(8).  
It is predicted that the SA program will prevent 64-70% of cancers, if all aspects of the 
program work effectively(8, 11). The long interval between pap smears for screening has not 
been evaluated. It may be that shortening the interval in this setting with a high prevalence 
of disease may still be cost-effective. Repeat screening has also been advocated to address 
the poor sensitivity of the conventional Pap smear(12). 
Justification for the Study: 
With long screening intervals a test with a high sensitivity would be desirable, 
sensitivity of Pap smear screening  is between 50% and 70% for detecting cervical 
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intraepithelial neoplasia 3 (CIN)(13). One of the reasons for such a big difference in 
sensitivity in different settings may be due to lack of clear definitions regarding disease 
thresholds. A screening test that misses CIN3 and above is, however, unacceptable. Repeat 
screening of negative and inadequate smears(12) and automated screening, may reduce 
false negatives. The majority of missed lesions are due to failure to sample adequately.  
The International Agency for Research on Cancer (IARC) working group has reported 
that inter-screen intervals of up to 5 years(14)  is protective; a case-control study in SA has 
also shown a protective effect with ever having had a pap smear of 60%(15).  In this study 
the protection is increased with three Pap smears and decreased with length of time from 
last Pap smear. The OR was 0.3 (95%CI: 0.2-0.4) when the last smear was performed within 
the previous 5 years and 0.5 (95% CI: 0.4-0.7) when the last smear was approximately 15 
years ago and the trend test was significant with a p=0.00.    
Reports from other situations have shown that long intervals and missed screening is 
associated with the development of invasive malignancy(16, 17).   
In 2011, the second round of cervical cancer screening should begin, it would be 
important to provide information that may aid policy-makers in making the inter-screen 
interval shorter or keeping it at 10 years. 
It would also be useful to know which women are at a high risk of developing cervical 
abnormalities after a pap report of ‘normal cytology’. One of the priorities for research 
identified by the WHO consultative process was to evaluate the need for repeat Pap smears 
by age(9).   
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This study will therefore determine the incidence of abnormal Papanicolaou (Pap) 
smears 12-24 months after a first normal Pap smear in an HIV negative population. Risk 
factors which predict an abnormal Pap smear 12-24 months after a normal Pap smear will 
also be explored. 
 
Literature Review: 
In this section, the role of HPV in cervical cancer is clarified. The natural history of CIN is 
discussed briefly and Pap smear screening in different countries is reviewed. Pap smear 
screening has not been able to eliminate cancer of the cervix, possible reasons for failure is 
explored. The high burden of disease in SA is also a cause for concern. Risk factors for Pap 
smear abnormalities are also discussed.  The chapter ends with a description of the aims and 
specific objectives of the study.  
The strength of association for HPV and cancer of the cervix, with an OR of more than 
50(18, 19) provides important but not sufficient evidence for cause. Molecular epidemiologic 
evidence indicates that cervical cancer and pre-cancer are almost certainly caused by HPV. 
Persistent infection with high risk genotypes (called types) of HPV is necessary for the 
development of dysplastic change within the cervix (20, 21). The strength of the 
carcinogenicity amongst the different HPV types also varies. Most women will however clear 
the infection. HPV types classified as high risk in a large population based study showed a 
strong concordance between the newly diagnosed evolutionary groupings with the risk of 
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progression to CIN3 and cancer (high risk types -
16/18/26/31/33/35/39/45/51/52/53/56/58/59/66/68/73/82)(21)  
There is a long period of between 10-20 years from HPV infection to dysplasia and to 
invasive cancer. A cohort of women in New Zealand between the years 1965 and 1974 were 
seen for cytological abnormalities and not treated. Pap smear data belonging to this cohort 
of women was linked to data from a cancer registry and has provided the most direct 
information regarding the natural history of CIN; with a cumulative incidence of cancer of the 
cervix of 31.3 % (95% CI=22.7-42.3) at 30 years and 50.3% (95% CI=37·3–64·9) at 50 years in 
women with CIN(22). 
The options of preventing cervical cancer may be at a primary or secondary level. The 
association of HPV and cervical cancer(23) was first shown in 1980 and lead to the 
manufacture of vaccinations and the possibility of primary prevention. Vaccination using the 
bivalent HPV vaccine was associated with a reduction of CIN2 and CIN3 caused by HPV 16/18  
of 93%, and a reduction of 53% when the HPV type was 31/33/45/52/58(24). It is unlikely 
that vaccination will eradicate invasive cervical cancer and the real effect on cervical cancer 
will only be known in 20-30 years. Other methods of preventing HPV infection like condom 
use and circumcision(25) have not been evaluated in populations, even though condom use  
has been shown to reduce HPV transmission(26) 
Secondary prevention with pap smear screening introduced in the 1950’s resulted in a 
reduction of cancer of the cervix in developed countries and this occurred prior to the 
knowledge of the association of HPV with cervical cancer. 
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Secondary prevention of cervical cancer is possible because of this long Natural History 
and the ability to treat the pre-malignant phase. Screening for pre-malignant cervical lesions 
is far from perfect. There are several controversial issues regarding when to screen, who to 
screen and how often to screen.  Screening too often may lead to over-treatment, anxiety 
and can be expensive. The figure below provides a conceptual framework of where screening 
may fail.  The focus of this study is shown in the dark black boxed area. 
 
Figure 1: Conceptual Framework of Pap smear screening showing reasons for failures 
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   Screening guidelines vary from country to country depending on the epidemiology of 
the disease and the cost. All the established screening protocols involve cytological 
screening. The table below summarizes some of the published guidelines.  
 
 
Table 1: A Summary of cervical screening from published guidelines 
Authority Screening Initiation Screening Intervals Screening Cessation 
South Africa, 2000 (8) Age of 30  Every 10 years 60 
Cancer Care Ontario, 
Canada, 2005(27) 
Three years after the 
first intercourse 
-Annually until 3 normal 
Pap and then after 
every 2-3 years 
70 
IARC, 2004(28) 25 years Every 3 years for 
women 25-49 years 
Every 5 years for 
women of 50 and above 
65 years 
ACOG, 2003(29) 21 years (or 3 years 
after intercourse) 
Annually for women 
under the age of 30. 
Every 2-3 years for 
women over 30 years 
Not enough evidence to 
determine 
ACS, 2002(29) 21 years (or 3 years 
after intercourse) 
Annually for women 
under the age of 30. 
Every 2-3 years for 
women over 30 years 
70 years 
USPSTF, 2002(30) 21 years (or 3 years 
after intercourse) 
At least every 3 years 65 years 
NZGG, 1998(31) 20 years (for sexually 
active women) 
Every 3 years 70 years 
CTFPHE, 1994(32) All sexually active 
women should be 
screened 
Every 3 years and high 
risk women more 
frequently 
No comment 
 
The Dutch program began in 1980, inviting women between the ages of 35 and 53 every 
3 years; this was revised in 1996 to include women between the ages of 30 and 60 every 5 
years(33). The SA program targets women in the age category with the highest incidence of 
invasive cancers.  
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The prevalence of abnormal Pap smears in SA is high. The prevalence of abnormal pap 
smears in a multicentre study of over 20 000 women in 2002 was 4.69% (LSIL, HSIL, or 
invasion) (11). A study by medical students, looking at 5 local clinics within the Johannesburg 
Metropolitan area between July- 2004 and Dec 2004 found that 12.8% of these pap smears 
were abnormal(34). This is similar to the proportion of abnormalities of 13.7% in all clinics in 
this  area in July- Dec 2006(35). It is not known whether this high prevalence of abnormal 
pap smears is due to the increase in the number of women who are HIV infected and who 
are also being screened with pap smears. 
Screening in SA prior to 2001, had been mainly opportunistic and did not target women 
at high risk of cervical disease. Establishment of a project to screen women in Soweto in 
1982 screened 32 365 women, but the number screened the next year was decreased by 
almost a third. The project was abandoned in 1986. The failure was attributed to failure in 
prioritizing screening in primary health clinics and failure in establishing a community 
education program(36).   A study in 1994 showed that screening in the Western Cape over a 
5 year period screened mainly pregnant women under the age of 30(37).  Cronje et al, in 
1985 showed that screening in the Free State target only 19% of women between the ages 
35-44 and that there were only 16% in women over the age of 45. Furthermore 53% of the 
women were white even though they made up only 21% of the population(38).  Screening in 
SA at present is erratic and has not reached the required coverage.  There are still many 
challenges within the program. While attempting to achieve the 70% target for coverage 
some women will be due for their second round of screening so studies of interval length will 
aid in making decisions for individual women. 
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Cancers which occur within the time interval between prescribed screenings are termed 
“interval cancers”. The figure below summarizes the factors which may lead to interval 
cancers in a screening program. 
 
Figure 2: Schematic outlining causes of interval cancers 
These may be new cancers or missed cancers due to sampling difficulties or due to errors 
in reporting. In a French study there were 148 cancers in women who had had some 
screening, 17% of whom had been adequately screened(16). Among women with interval 
cancers in an Australian study(17), review of the negative slides found that most were due to 
suboptimal sampling or to errors in reporting. Most reports of interval cancers occur in 
women under the age of 35, and whether this is due to greater participation of younger 
women in screening services or because cervical cytology is less effective in preventing 
cancers in younger women is not known.  
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Reasons may be that the lesion did not exfoliate or that a particular malignancy 
progressed too rapidly for detection by screening. These should however be minimized and 
diagnosed at an earlier stage in a setting where there is organized screening. Many studies 
have shown that women with cancer of the cervix had been less well screened than  
controls(14, 39). False negative pap smears occur more commonly in women with invasive 
cervical cancer(40) than with CIN2 and CIN3(41). 
Protection conferred by a negative Pap smear: 
Even though screening with Pap smears has limitations, some screening is better than 
none. A study using the Finnish Cancer registry showed that the risk of CIN3 was low 
immediately after a normal Pap smear and then increased over the following 5 year 
period(42). A case-control study in SA also showed that having ever had a Pap smear is 
protective, but that the protection wanes when the Pap smear was performed more than 5 
years ago(15). 
A meta-analysis of screening programs found no age difference in the protection 
conferred by a negative Pap smear in the 1960’s and 1970’s(14). Sasieni et al showed that 
the protective effect of a negative pap is less in younger women (20-39) than in women aged 
40 or older. As a result they advocated shorter screening intervals for younger women(4).  
 
Repeat testing within two years, has been used in many screening programs to increase 
the sensitivity of the Pap smear(29)  however this has not been shown to be associated with 
a reduction in invasive disease in the British system(4).  
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Savings to the health system may derive from substantially increasing the duration of the 
interval between screens without losses in sensitivity for high-grade intraepithelial lesions by 
adding Human Papillomavirus (HPV) testing to the screening. HPV testing has a high negative 
predictive value(43, 44) and would therefore enable a longer interval of screening. 
 Unnecessarily screening too often may lead to an increase in false positives, increased 
cost and increased anxiety for women who are being screened. 
Histological Type: 
 The protection offered against adenocarcinoma of the cervix with Pap smear screening is 
not clear. Cytological screening in the 1970’s and 1980’s(45) showed little protection while a 
study in the 1990’s indicated that there was some protection from a negative Pap smear, 
although to a lesser extent than for squamous malignancy. An annual increase of 
Adenocarcinoma in situ of 12.25% between 1973 and 1995 was reported by the US National 
Cancer Institute Surveillance, Epidemiology and End Results database (from 0.02/100 000 to 
0.61/100 000), was reported(46). It is not clear whether this is a real increase or whether it is 
a reflection of better reporting.  
A series reported in Australia showed that of  the adenocarcinomata  detected on 
histology  88% were  reported as  a high grade abnormality on the Pap smear(47).  
Risk factors associated with cancer of the cervix: 
 Several guidelines consider risk factors in the suggested intervals for cervical cancer 
screening, in particular HIV(27, 48). The South African guidelines make provision for Pap 
smear on the basis of a woman’s medical history, that is that any woman with any 
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gynaecological complaint requiring a Pap smear should receive a Pap smear as part of the 
routine gynaecological examination.  
Risk factors like multiparity(49) , smoking(50), sexually transmitted infections (STI) like 
Chlamydia and Herpes(51) and oral contraception (>5years) (46) have also been associated 
with cervical neoplasia. 
Oral contraceptive use has been associated with cancer of the cervix both directly and 
indirectly, with long term users at 3-4 times increased risk for cervical cancer(52). However a  
subsequent study has shown that the risk of cervical cancer in HPV negative users of COC 
was not higher(53).   
The availability of the oral contraceptive pill in the sixties made condom usage the 
method used in only 25% of sexually active individuals(54). At least 80% of unmarried 
females who use hormonal contraception have been shown to omit condom use(55). 
Increased Chlamydia,  Mycoplasma and other STD’s have been shown to be associated with 
hormonal contraception(56), probably as a result of the reduction in condom use.  
 Condom usage has  been shown to be associated with lower transmission(26), 
persistence(26) and seropositivity(57) of HPV. Observational studies have found that the 
diaphragm has been associated with a reduction of some genital infections(58), a 
randomized trial however showed no difference in incidence of HPV between the diaphragm 
and condom(59).  
HSV is a marker of previous unsafe sex, with seropositivity of up to 60 % in attendees at 
sexually transmitted disease clinics(60).  Therefore the increased risk of cervical cancer 
14 
 
associated with HPV and HSV co-infection(61) may be related to other correlates of unsafe 
sex. 
Higher frequency of intercourse has been shown to increase the risk of both HPV 
infection and cervical cancer(62) –suggesting a dose response . Safe sex practice appears to 
be beneficial in women who are HPV infected, longer durations of safe sex in women with 
HPV infection is associated with reduced incidence of cervical intra-epithelial neoplasia(63), 
and resumption of safe sex is associated with a regression of neoplasia(64). 
Observational studies have shown that cervical cancer is reduced in communities  which 
practice male circumcision(65).  Recognizing the role of HPV in causing cervical a cancer and 
with better methods of detecting HPV, it has been shown  that there is a reduction in the 
detection of HPV in women whose male partners had been circumcised(25). A similar 
protective effect was shown in a randomized control trial of the effect of circumcision on the 
presence of genital HPV in female partners. However the effect on CIN could not be 
quantified(66). 
 
Aim of the study: 
The purpose is to determine the proportion of women who develop an abnormal Pap 
smear 12-24 months after a normal pap smear. Risk factors associated with the Pap smear 
abnormalities may be important in determining the optimum screening interval for certain 
subgroups of women.  
Specific Objectives: 
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• To determine the incidence of Pap smear abnormalities in a Cohort of women in 
Soweto, 12-24 months after a normal Pap smear. 
• To determine the incidence of Pap smear abnormalities after an inadequate Pap 
smear. 
• To determine the incidence of Pap smear abnormalities 12-24 months after a normal 
or inadequate Pap smear. 
• To investigate factors associated with the development of an abnormal Pap 12-24 
months after a previously normal or inadequate Pap smear. 
Chapter 2: Methodology:  
This is a secondary analysis of data collected during the  “Methods for improving 
Reproductive Health in Africa” (MIRA) trial which was a randomized control trial on the use 
of the diaphragm, lubricant gel plus condoms versus condoms alone in  preventing HIV 
infection in women(67).  Women were offered a Pap smear at enrollment and again at exit 
as optional tests. The outcome of interest is the incidence of abnormal cytology 12 to 24 
months after a normal Pap smear.  
Primary data-set: 
All women were screened for HIV infection and STI’s prior to enrollment.   
After signing a consent form for the screening procedures they were asked to do a 
questionnaire on demographics and condom use. They then were counseled on HIV and 
STI’s. Urine was taken for PCR testing of Chlamydia trachomatis, Neisseria gonorrhea and 
Trichomonas vaginalis.   A blood sample from a finger-prick or venous puncture was obtained 
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for rapid HIV testing (Oraquick® and Determine®). The women were notified about the HIV 
result and there was post test counseling for both positive and negative women. Women 
with equivocal results would have a confirmatory laboratory ELISA test. 
At the enrollment visit, a pelvic examination was carried out on all women including a 
speculum examination to determine the presence of a healthy cervix.  At this visit all women 
were also offered a Pap smear (the protocol requirements were that all women who had not 
had a Pap smear in the last 12 months be offered a Pap smear).  The Pap smears were 
conventional smears that were performed by nurse clinicians that had all had primary health 
care training and had repeat training during the study period. All Pap smears were reported 
on by the NHLS cytopathology department.  NHLS is accredited by South African National 
Accreditation Society (SANAS).  The recommendations regarding management of Pap smear 
abnormalities were that any Pap smear where there was no endocervical or ectocervical 
component had to be repeated even when the descriptive diagnosis said “within normal 
limits”.  A pap report of LSIL or ASCUS – was repeated in 6 months, HSIL or AGS – was 
referred to Colposcopy.  
All STI results were discussed and all positive results had to be treated prior to entry into 
the trial. 
Women who met all eligibility criteria and joined the trial were provided an HIV 
prevention package which included male condoms, safe sex and risk reduction counseling 
and treatment of STI’s detected at any visit. Women were randomized into an intervention 
group of diaphragm and lubricant jelly and a control group (condoms only). 1028 eligible 
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women were enrolled at the Perinatal HIV Research Unit in Soweto, Johannesburg. Women 
were followed up every 3 months for HIV and other STI’s.   
Information on socio-demographic factors, history of sexual behavior, a gynaecologic 
history, a medical history, clinical examination, and urine and blood tests for STI’s were 
sought. The medical history and demographic information was obtained through interviewer 
administered questionnaires and Audio-Computer Assisted Self-Interview (ACASI).  
Study Population: 
The study population was recruited at family planning clinics, well baby clinics and from 
the community in Soweto.  “Screening” should be of women who are asymptomatic and 
these women would be different from women presenting to a clinic with a complaint. 
However the women in this study are a decade younger than the prescribed age of screening 
in the SA guidelines. Recruitment began in March 2004.   These women are drawn from a 
population in Soweto which is a high prevalence area for cervical abnormalities(34, 35). This 
data may therefore aid in evaluating the intervals at which Pap smears should be performed 
in an HIV negative population.  
Women who had a Pap smear at both the beginning and the end of study form the study 
population. 
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Eligibility Criteria for women in the MIRA trial: 
Table 2: Eligibility and Exclusion criteria used in primary study and how it would affect this present study 
Eligibility criteria for this study How this is expected to affect the study 
Age: 18-49 years Weakness, Pap smear screening:30-60 years 
HIV- Negative within 14 days of enrollment Strength, because the participant’s status is known 
Chlamydia trachomatis -Negative 
Tested within 30 days of enrollment or 
treated 
Weakness, No indication of symptomatic or not. In clinical 
scenario Chlamydia testing would only be done if woman 
was symptomatic 
Neisseria gonorrhea- Negative 
Tested within 30 days of enrollment or 
treated 
Weakness, No indication of symptomatic or not. In clinical 
scenario Gonorrhea testing/treatment would only be done if 
woman was symptomatic 
Cervix on speculum examination- Normal Strength, Pap smear can only be done if cervix normal  
Planning to live in area for next 24 months Strength, reduces loss to follow-up 
Willing to be randomized and follow protocol Strength 
Willing to consent Neither strength nor weakness 
History of Toxic Shock syndrome Neither strength nor weakness, number of women very small 
Allergy to latex Neither strength nor weakness 
Currently pregnant or desiring to be pregnant Neither strength nor weakness 
No cervix Strength, the risk of disease in women who have had a 
hysterectomy is different and very low if there has never 
been cervical disease. 
Refuses treatment for an STI Weakness, now not able to assess risk in these women, but 
small number of women 
No pelvic surgery or pregnancy in last 6 
months 
Neither strength or weakness 
Presence of clinically apparent lesion Strength, these women would be screened anyway if 
presented to a clinic 
Injected illicit drugs in last 12 months Neither strength nor a weakness 
Unable to use diaphragm Neither strength nor a weakness 
Participation in any other clinical trial Strength, the effect of any other vaginal product may affect 
the Pap smear. 
Unable to speak English, Zulu, Shona or Sotho Weakness, may exclude women from rural areas who may 
have a different risk. 
Other conditions which in the opinion of the 
investigator would compromise the integrity 
of the trial 
Strength, need good follow-up 
Does not meet eligibility criteria within 5 visits Neither strength nor a weakness 
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Study Design: 
Secondary data analysis of a Randomized control trial. This is a longitudinal cohort of all 
participants who were randomized to a diaphragm, lubricant gel and condoms or to 
condoms only. They had to have had a normal or inadequate Pap smear at enrollment and 
then had a repeat Pap smear.  
Study variables: 
Variables that were extracted to be studied were those that were known risk factors for 
cancer of the cervix, socio-demographic variables and clinical factors that would make a 
woman interact with a health care worker. Such an interaction may allow opportunistic 
screening and may be a time when a repeat Pap smear may be performed. 
Socio-demographic Variables: 
Age, years of education, number of rooms in the home, number of housemates, married, 
living with husband/ partner. 
Pregnancy History: 
Parity, live births, abortions, miscarriages, mode of delivery. 
Sexual history: 
Age at first intercourse, number of sexual partners 
Medical history & examination: 
Current and past contraceptive use, history of TB, hypertension, diabetes, admission to 
hospital, blood transfusion, Hepatitis. History and clinical findings suggestive of sexually 
transmitted disease.  
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Gynaecological history and examination: 
History of abnormal vaginal bleeding over the last 3 months, vaginal discharge, vaginal 
odor, any vaginal lesions  
Laboratory Tests: 
Pap smear results at enrollment and any repeat during the trial. 
Chlamydia trachomatis (Urine PCR), Neisseria gonorrhea (Urine PCR), Trichomonas 
vaginalis (urine PCR) testing at all visits. 
Herpes (Focus HSV-2) and Syphilis (RPR and TPHA in those women with a positive RPR) 
results at enrollment and exit.  Only those women who tested negative for Herpes had a 
repeat test at exit. 
HIV infection at all visits ((Oraquick HIV=1/2 Rapid Test and Determine-HIV-1 Rapid test) 
and HIV DNA for confirmation, HIV ELISA discordant initial testing) 
 
Data Analysis: 
Any variable that was thought to be associated with cancer of the cervix or dysplasia was 
explored for association. The tables with the socio-demographic data was merged with 
tables containing Pap smear results, medical history, gynaecological history, clinical findings 
of an STI  and with every table that contained results for every STI- thereby creating a 
“master dataset”. The tables were already in a dta. format.  There were 5 duplicates, which 
were then deleted. All analysis was done using STATA 10 statistical software (Stata Corp, 
Texas, USA). 
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 A new variable: “Pap smear abnormality” was made which was the outcome of interest. 
The Pap smear findings at exit were coded, with “0” representing normal or inadequate, and 
“1” LSIL, HSIL, ASCUS, ASC-H. There were no Pap smear results of invasion or AGUS. Another 
variable “follow-up time” was made and this was the date from the first Pap smear 
(enrollment) to the date of the repeat Pap smear. This was useful in modeling time to 
abnormal cytology (incidence) using the Cox proportional hazards model.  
The explanatory variables were mainly baseline variables. HIV infection, Chlamydia PCR, 
Gonorrhea PCR, RPR, HSV Elisa, were also exit variables.  
All the explanatory variables were compared in those individuals who continued to have 
a normal Pap smear versus those who developed abnormal cytology.  The Cross Tabulation 
tables were performed with every explanatory variable and the outcome. For the numeric 
(continuous) variables– the Wilcoxon rank sum test was used to test the equality of the 
median values where the variables were not normally distributed. Normality was assessed 
both graphically (using box and whisker plots and histogram plots) and statistically (using the 
Shapiro-Wilk test). For normally distributed numeric variables the ttest was used. All 
categorical variables were compared using the chi2 test or the Fisher exact test for those 
that had fewer than 5 observations in a cell. 
To compare the risk of an abnormal Pap smear in those with a normal Pap smear at 
baseline with those with an inadequate Pap smear at Baseline Kaplan – Meier curves for 
both cohorts were drawn and the equality of both curves tested using the log rank test. 
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Logistic regression models were used to find the risk factors associated with the 
outcome. Univariate analysis was first performed and crude odds ratios for the association of 
these variables with an abnormal Pap smear was noted. Multivariate models were built using 
variables where the p-value was less than 0.2 and interaction issues assessed for. All 
variables of interest were included in the multivariate model and backward selection 
procedure was performed. The assumption of linearity in the logit scale was also assessed 
and the Hosmer – Lemeshow goodness of fit test was used for model diagnostics. Also the 
sensitivity of the model was obtained and graphs of the receiver operator characteristic 
(ROC) curves for both models were plotted. 
Ethical Considerations: 
Ethical clearance was obtained from the Human Research Ethics Committee (Medical) in 
June 2009. The Clearance number was M090676 (Appendix 1). Permission for the use of the 
data was obtained from Liz Montgomery and Heidy Fancher for the MIRA Investigators 
(Appendix 2). 
Chapter 3: Results  
This chapter begins with an outline of the flow of participants through the trial, who form 
the study population. The Pap smear results for participants who had a Pap smear at entry 
and exit is then tabulated. The Incidence of abnormal Pap smears in the whole group and in 
women with a normal Pap smear results is shown.  The tables that follow are a description 
and comparison of every variable that was included in the study. Finally, the results of a 
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univariate and multivariate analysis is shown. This analysis was done to find risk factors 
which may predict an abnormal Pap smear on a repeat test between 12 and 24 months. 
There were 850 women amongst those eligible for the study that had a repeat pap 
smear. Ninety seven women (11.41%) had an abnormal Pap smear at entry and would be 
excluded. Figure 3 shows the flow of participants eligible for the study and Table 3 shows the 
type of cytological abnormalities that were detected at enrollment and when repeated. 
 
 
Recruited 
1872- Participants 
Enrolled 
1028- Participants 
Pap smear at entry 
850- Participants had a 
Pap smear performed at 
entry into the study 
Sample  
753- Participants with 
normal or inadequate pap 
smears at entry and a 
repeat Pap  
Excluded: 97 with an 
abnormal Pap smear. 
Excluded:  
108 did not have a Pap 
smear  
70 had a pap smear at exit 
only 
Figure 3: Flow chart of participants 
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Table 3: Cytological results on Pap smear at baseline 
 Categories of Pap smears at enrollment  
Categories 
of Pap 
smears at 
repeat 
Testing 
(Bold and 
in italics) 
 
 Normal and 
Satisfactory 
for 
evaluation 
LSIL ASCUS HSIL Inadequate 
Pap smear 
Total 
Normal 476 
(88.97%) 
31 
(60.78%) 
21 
(67.74%) 
8 
(53.33
%) 
193  
(88.53%) 
729 
(88.53%) 
Any 
abnormality 
(LSIL, ASCUS, 
HSIL) 
59  
(11.03%) 
20 
(39.22%) 
10 
(32.26%) 
7 
(46.67
%) 
25 
(11.47%) 
121 
(14.24%) 
Totals of pap 
at enrollment 
535 
(62.94%) 
51 
(6%) 
31 
(3.65%) 
15  
(1.76%) 
218 
(25.65%) 
850 
(100%) 
 
The incidence of cytological abnormalities in this group of women (Baseline Pap normal 
or inadequate) was 7.33% per annum. The median follow-up time was 297 days (IQR182-
455). The incidence of cytological abnormalities is 6.48 % in women with a previously normal 
Pap and 11.71% in women with an inadequate smear result.   The graphs depict the risk of 
having an abnormal Pap smear. 
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                Figure 4: Abnormal cytology on repeat testing in the whole sample.  
 
0.00 
0.25 
0.50 
0.75 
1.00 
0 .5 1 1.5 2 2.5 
analysis 
time 
Kaplan-Meier survival estimate for women with normal and 
inadequate Pap smear initially 
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Figure 5: Abnormal cytology on repeat testing after a normal or inadequate Pap smear 
 
The log-rank test for equality of survivor function indicates that there is a statistically 
significant difference in the risk of a cytological abnormality after a normal when compared 
to an inadequate Pap smear (p=0.03). 
Less than half a percent of both the normal and inadequate Pap smears had a HSIL 
reported on their subsequent Pap smear and the rest of the abnormalities were LSIL and 
ASCUS (table 4). However the presence of any cytological abnormality would mean that that 
woman is at risk of cervical cancer albeit with a different degree of risk. The analysis will 
therefore combine all cytological abnormalities as the outcome of interest. 
0.00 
0.25 
0.50 
0.75 
1.00 
0 .5 1 1.5 2 2.5 
Analysis time 
pap smear= normal pap smear= inadequate 
Kaplan-Meier survival estimates for normal OR inadequate Pap smear initially 
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Table 4: Cytological findings on the second Pap smear  
First Pap Normal Inadequate Total  
Normal 460 (85.98%) 177 (81.19%) 637 (84.59%) 
LSIL 39 (7.29%) 13 (5.96%) 52 (6.91%) 
ASCUS 18 (3.36%) 11 (5.05%) 29 (3.85%) 
HSIL 2 (  0.37%) 1 (0.46%) 3 (0.40%) 
Inadequate 16 (2.99%) 16  (7.34%) 32 (4.2%) 
 535 218 753 
(p=0.00) 
Demographic characteristics: 
     Comparing socio-demographic factors with having an abnormal repeat pap smear is 
shown in the table 5 below.  There were no differences of statistical importance in the 2 
groups. 
Table 5: Description and comparison of socio-demographic factors in women with normal and abnormal 
cytology at repeat Pap smear. 
 Totals 
n=753 
Abnormal Cytology 
n= 84 (11.16%) 
Normal Cytology 
n=669 (88.84%) 
p-value 
Age: Mean=29.19(sd-8.11) 
Median 28 (iqr-22-35) 
Range= 18-48 
Mean=28.04 (sd-8.18) 
Median= 25 (iqr13.5) 
Range=18-48 
Mean=29.33 (sd-8.09) 
Median=28 (iqr-14), 
Range 18-48 
 
0.17*  
0.13** 
Education in 
number of years 
Mean=10.94 (sd-2.25) 
Median=12 (iqr-10-12) 
Range=0-17 
Mean=10.85 (sd-2.34) 
Median=12 (iqr-2) 
Mean=11.02 (sd-2.20) 
Median=12 (12 (iqr-2) 
0.51*  
0.49**  
Married n=165 (21.91%) 12(14.29%) 153 (22.27%) 0.07 (Chi2) 
 
Live with 
husband/partner 
N=319 (42.36%) 35 (41.67%) 284 (42.45) 0.89 (Chi2) 
Number of 
rooms at home: 
Mean =3.44 (sd-1.73) 
Range 1-10 
Mean=3.39 (1.74) 
Median=4(2) 
Mean=3.45(1.73) 
Median=4(2) 
0.79*  
0.87**  
Number of 
Housemates 
Mean=4.85 (sd-2.20) 
Median=4(iqr-3) 
Range=8-15 
Mean=4.54 (sd-1.92) 
Median= 4(iqr-2) 
 
Mean=4.89 (sd-2.23) 
Median =4 (iqr-3) 
0.17*  
0.12***  
0.14**  
Children 
currently being 
care for 
Mean= 1.66 (sd-1.46) 
Median 1(iqr-1) 
Range=0-7 
Mean=1.60 (sd-1.65) 
Median 1(iqr-1) 
Mean 1.67 (sd-1.44) 
Median = 1(iqr-2) 
0.60*  
0.29**  
*ttest with equal variances **Wilcoxon rank-sum ***ttest with unequal variance 
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Participants were not asked about smoking or alcohol use. The use of vitamins, medical 
supplements or herbs was not associated with having an increased risk of an abnormal pap 
smear (p=0.91) 
Contraceptive Use:  
Women were asked about contraceptive use and their current method. They were 
unfortunately not asked about the length of time that they had used the method. None of 
the women had used the diaphragm, spermicides or were with a partner who had had a 
vasectomy. There was no statistical difference in the use of non-barrier methods in these 
women (table 6). 
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Table 6: A description and comparison of non-barrier contraception 
 
****Fisher’s exact for any cell with less than 5 observations 
 
The use of Barrier Methods of contraception: 
There were fewer women with cervical abnormalities in those who were randomized to 
the control group. “Condom use at last intercourse”  as a probe of condom use is often 
n=753 Abnormal Cytology 
n= 84 (11.16%) 
Normal Cytology 
n=669 (88.84%) 
p-value 
Combined oral 
contraception- ever 
n= 235 (31.21%) 
24 (28.57) 211 (31.54) 0.58 (chi2) 
 
Combined oral 
contraception- current 
n=58 (7.70%) 
9 (10.71) 49 (7.32) 0.27 (chi2) 
 
Injectable Hormones-ever  
n=564 (74.90%) 
62 (73.81) 502 (75.04) 0.81 (chi2) 
Injectable hormones- 
current n=223 (29.61%) 
26 (30.95) 197 (29.45) 0.78 (chi2) 
POP -ever  
n=91 (12.08%) 
9 (10.71) 82 (12.26) 0.86**** 
POP -current  
n=20 (2.66%) 
1 (1.19) 19 (2.84) 0.72****  
Ever used hormonal 
contraception 
n=619 (82.20%) 
65 (77.38) 554 (82.81) 0.22 (chi2) 
Tubal Ligation 51 (6.77%) 4 (4.76) 47 (7.03) 0.64**** 
Ever used an IUD 
n=86 (11.42%) 
7 (8.33) 79 (11.81) 0.35 (chi2) 
 
Current use of an IUD  
n=7 (0.93%) 
0 (00) 7 (1.05) 1****  
Ever used Natural Methods 
n=8 (1.06%) 
2 (2.38) 6 (0.90) 0.22**** 
Currently use Natural 
Methods n=2 (0.27%) 
1 (1.19) 1 (0.15) 0.21**** 
Ever used Withdrawal  
n=17 (2.26%) 
2 (2.38) 15 (2.24) 1**** 
Current use of withdrawal 
n=6 (0.80) 
0(00) 6 (0.90) 1**** 
Ever used Traditional 
Methods n=3 (0.40) 
0 (00) 3 (0.45) 1**** 
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thought to be best  way of assessing use because it reduces re-call bias, however in this 
analysis it was not different in the 2 groups, even on stratifying by randomization. 
Interestingly there were more women in the diaphragm group with abnormal cytology. The 
prevalence of female condom use is low in this group of women and not different in the 2 
groups. The use of “female condoms” was discouraged owing to probable problems with 
fitting for women in the intervention arm. 
 
Table 7: A description and comparison of Barrier contraception 
n=753 Abnormal Cytology 
n= 84 (11.16%) 
Normal Cytology 
n=669 (88.84%) 
p-value 
Randomized to the 
intervention arm 
n=388 (51.53) 
53 (63.10) 335 (50.07) 0.02 (chi2) 
Randomized to the control 
arm 
365 (48.47) 
31(36.90) 334 (49.93) 
Condoms used at last 
vaginal sex 
438 (71.57) 
46 (64.79) 392 (72.46) 0.18 (chi2) 
 
Ever used condoms 
586 (77.82) 
64 (76.19) 522 (78.03) 0.70 (chi2) 
Current condom use (at 
baseline) 
506 (67.20%) 
53 (63.10) 453 (67.71) 0.40 (chi2) 
Female condoms used at 
last intercourse 
27 (4.41%) 
4 (5.63) 23 (4.25) 0.54 **** 
****Fisher’s exact used when there were fewer than 5 observations in a cell. 
 
Pregnancy History: 
Increase parity has been associated with an increase in risk of cancer of the cervix; the 
table below shows no significant association with parity. The history of ever having had an 
ectopic pregnancy has the most impact on the outcome.   
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Table 8: A description and comparison of pregnancy history. 
 Totals 
n=753 
Abnormal Cytology 
n=84 (11.16%) 
Normal Cytology 
n= 669 (88.84%) 
 
p-value 
Pregnancies Mean=1.8 (sd-1.48) 
Median=2 (1-3) 
Range=0-7 
Mean=1.77 (sd-1.62) 
Median =1(1-3) 
Mean =1.81 (sd-1.47) 
Median=2 (1-3) 
*0.84 
**0.54  
Number of live-
births 
Mean=1.64 (1.38) 
Median =1 (0-2) 
Range 0-7 
Mean=1.54 (sd-1.50) 
Median= 1(0-2) 
Mean=1.65(sd-1.37) 
Median=1 (0-2) 
*0.46 
**0.24  
 Vaginal births Mean=1.46(sd-1.39) 
Median=1 (iqr-0-2) 
Range=0-6 
Mean=1.44 (sd-1.54) 
Median=1(0-2) 
Mean=1.46 (sd-1.37) 
Median= 1(0-2) 
 
*0.91 
**0.54  
Vaginal Births if 
ever pregnant 
n=686 
mean =1.59 (sd-1.37) 
Mean= 1.52 (sd-1.54) 
 
Mean=1.60 (sd-1.35) 
 
*0.62  
 
Number of 
women who have 
ever had a 
caesarian section 
Mean 0.22 (sd-0.56) 
No of Caesars= 120 
Mean= 0.19 (sd-0.51) 
 
Mean= 0.22 (sd-0.57) 
 
*0.62 
 
Termination of 
pregnancy 
n=14 (1.87%) 
Mean=0.02 (sd-0.15) 
Mean=0.02 (sd-0.14) 
 
Mean 0.02 (sd-0.15) 
 
*0.80 
 
Termination of 
pregnancy if ever 
pregnant 
14 (1.99%)  2(2.41%) 
 
 12(1.94%) 0.68 **** 
 
Miscarriage if ever 
pregnant 
n=42 (5.97%) 5 (6.02%) 37 (5.97%) 1 **** 
Ectopic pregnancy 
if pregnant 
 4 (4.82%) 10 (1.61%) 0.07 **** 
Any poor 
pregnancy 
outcome 
n=64 (8.58%) 11 (13.25%) 53 (7.99) 0.14**** 
*ttest ** Wilcoxon ranksum ****Fishers exact 
Medical History and Other Medical Conditions: 
Women who attend Community health care facilities may be offered a Pap smear as part 
of the opportunistic screening service. A comparison of medical conditions that women 
present with may be helpful in determining which women should be offered a repeat Pap 
smear more frequently than is suggested by the National guidelines. Below is a comparison 
of the medical history in these women. Women who were admitted to hospital for any 
reason (not birth related) were statistically more likely to have an abnormal Pap smear. 
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Table 9: A description and comparison of symtoms that a woman may present with. 
n=753 Abnormal Cytology 
n=84 (11.16%) 
Normal Cytology 
n= 669 (88.84%) 
 
p-value 
History of TB 
N=23 (3.08%) 
3 (3.61%) 20 (3.02%) 0.73****  
 
History of Urinary tract 
infection 
24 (3.22%) 
2 (2.41%) 22 (3.32%) 1****  
 
History of Hypertension 
67 (8.98%) 
7 (8.43%) 60 (9.05%) 0.85 (chi2) 
 
History of Hepatitis 
1 (0.13%) 
0 (00%) 1 (0.15%) 1**** 
 
History of Diabetes 
2 (0.27%) 
 
0 (00%) 2 (0.30%) 1****  
Non- Gynae visit to doctor 
113 (15.01%) 
11 (13.10%) 102 (15.25%) 0.60 (chi2) 
 
History of cervical biopsy/ 
cancer 
1 (0.13%) 
0 (00%) 1 (0.15%) 1**** 
History of admission to 
hospital- not birth related 
118 (15.82%) 
20 (24.10%) 98 (14.78%) 0.03 (chi2) 
 
History of Blood 
Transfusion 
26 (3.49%) 
2 (2.41%) 24 (3.62%) 0.76**** 
 
****Fisher’s exact 
 
Sexual History and Sexually transmitted disease: 
Exploring the association with sexual history and the incidence of an abnormal Pap smear 
is shown in the table below. Women with an increased number of sexual partners were more 
likely to have an abnormal Pap smear on repeat testing. The trial excluded women with less 
than 3 coital acts in the month and therefore it would not be meaningful to assess difference 
by coital frequency. Categorizing “age at first intercourse” to less than 17, 18 or 19 did not 
show ant statistical difference- data not shown. 
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Table 10: A description and comparison of sexual history 
Variable n=753 Abnormal Cytology 
n=84 (11.16%) 
Normal Cytology 
n= 669 (88.84%) 
 
p-value 
Age at first 
intercourse 
Mean= 17.58 (sd-2.12) 
Median=18 (iqr-16-19) 
Range=11-27 
Mean=17.32 (sd-1.78) 
Median=17 (16-19) 
Mean=17.61 (sd-2.15) 
Median=17 (16-19) 
0.24*  
0.18***  
0.26**  
Less than 20years 
at 1st intercourse 
n=647 (85.92%) 77 (91.67%) 570(85.20%) 0.11 (chi2) 
 
Sex in exchange Sex in exchange 
N=17(2.26%) 
4 (4.76%) 13 (1.94%) 0.11 **** 
Number of male 
partners 
Mean=4.02 (sd-2.90) 
Median=3 (iqr2-5) 
Range 1-26 
Mean= 4.85 (sd-3.40) 
Median=4 (2-5) 
Mean= 3.84 (sd-2.73) 
Median=3 (2-5) 
0.00* 
0.00**  
Average sex in the 
last 3 months: 
 
Mean= 9.46 (sd-5.12) 
Median= 8(iqr6-12) 
Range= 3-40 
Mean= 9.46 (sd-4.96) 
Median=8 (-4-12) 
Mean=9.46 (sd-4.96) 
Median=7 (5-12) 
1* 
0.39** 
*ttest **Wilcoxon ranksum ***ttest (unequal variances) **** Fisher’s exact 
 
Sexually transmitted disease is associated with cancer of the cervix. The tables below 
shows the association between history (Table 11) and clinical findings (Table 12) suggestive 
of an STI and confirmatory tests (Table 13) of STI’s with the risk of developing an abnormal 
cytology on Pap smear in these women. Some clinical findings (variables) were excluded 
from the analysis as there were very few women with such an abnormality. The clinical 
findings were really incidental findings, rather than complaints from the women as would be 
the case in a research setting.  Women were asked about symptoms suggestive of a sexually 
transmitted disease in the last 3 months and whether these symptoms were ongoing.  A 
history of a vaginal discharge in the last 3 months, or symptoms of an STI were important 
difference in the 2 groups of women. 
Table 11: A description and comparison of symptoms which are suggestive of a sexually transmitted disease 
n=753 Abnormal Cytology 
n=84 (11.16%) 
Normal Cytology 
n= 669 (88.84%) 
 
p-value 
Have you ever been 
treated for an STI? 
22 (26.51%) 131 (19.76%) 0.15 (chi2) 
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153 (20.51%) 
N=746 
Number of times treated  
Mean=1.26 (0.89) 
Mean=1.91 (1.95) 
 
Mean= 1.15 (0.49) 
 
0.00*  
0.08***  
Symptoms suggestive of 
an STI n=68(9.12%) 
15(18.07) 53 (7.99%) 0.00 (chi2) 
 
 
Abnormal bleeding in the 
last 3 months 
n=22 (2.95%) 
1 (1.20) 21 (3.17) 0.28**** 
 
Vaginal discharge on 
history in the last 3 
months 
n=37 (4.96%) 
11 (13.25) 26 (3.92) 0.00 (chi2) 
 
Ongoing vaginal discharge 
on history n=11 (4.69%) 
3 (3.61%) 8 (1.21%) 0.11**** 
 
History of vaginal odor in 
the last 3 months n=10 
(4.69%) 
1 (5%) 9 (4.66%) 1**** 
Ongoing vaginal odor  
5 (2.35%) 
1 (5%) 4(2.07%) 0.39**** 
History of genital 
irritation in the last 3 
months 12 (1.61%) 
1 (1.20%) 11 (1.66%) 1****  
 
History of ongoing 
irritation 5 (0.67%) 
1 (0.67%) 4 (0.60%) 0.45 **** 
History of ongoing genital 
sores 1 (0.13) 
0 (0.00) 1 (0.15) 1**** 
 
History of ongoing low 
abd pain not associated 
with periods 4 (0.54) 
1 (1.20) 3 (0.45) 0.38**** 
 
History of ongoing genital 
symptoms 
23 (3.08) 
5 (6.02) 18 (2.71) 0.17**** 
 
*ttest ***ttest (unequal variances) ****Fisher’s exact 
Clinical findings suggestive of Sexually transmitted diseases:  
All participants were examined and had a pelvic examination. There was only 1 (0.13%) 
with inguinal lymphadenopathy, 1(0.13%) of women with a perineal/perianal abnormality, 
7(0.94%) with a vulval abnormality, 3(0.40%) with a vaginal epithelium abnormality.  The 
quantity of vaginal discharge was graded into small, moderate and abundant and an 
increased quantity was not associated with the outcome. 
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The vaginal discharge was characterized as normal (2(0.27%)), thin flows easily 
(18(2.41%)) and thick, does not flow easily (16 (2.14%)). There was no statistical association 
demonstrated with this finding. The consistency of the discharge was described as non 
homogenous, normal (4(0.54%)); non homogenous abnormal (10(1.34%)), homogenous 
smooth (15(2.01%)) and homogenous frothy (7 (0.94%)).  
The cervix was examined for epithelial disruptions (0 women), mucus (0 women), 
quantity of mucus, and ectopy (0 women) and for contact bleeding. Table 10 shows those 
clinical findings that were more common. The pH of the vagina is normally less than 4.5. An 
analysis done with a pH which is greater than 5 did not show any statistical significance.  
Table 12: A description and comparison of signs suggestive of sexually transmitted disease. 
n=753 Abnormal Cytology 
n=84 (11.16%) 
Normal Cytology 
n= 669 (88.84%) 
 
p-value 
Vaginal discharge on 
clinical examination 
n=36 (4.83%) 
5 (6.02%) 31 (4.68%) 0.59**** 
Cervicitis n=30 (4.02%) 
same as PID 
5 (6.02%) 25 (3.77%) 0.37**** 
 
Clinician identified RTI 43 
(5.76) 
7 (8.43%) 36 (5.43%) 0.27 (chi2) 
 
Vaginal ph  
Mean= 4.35 (0.64) 
Median= 4.4 (4-4.7) 
Range=3-6.1 
Mean=4.29 (sd=0.62) 
 
Mean=4.34 (sd=0.57) 
 
0.52* 
 
Vaginal ph >4.5 
n=231 (30.68) 
32 (38.10%) 199 (29.75%) 0.12 (chi2) 
Vaginal ph >5 
=50 (6.64%) 
 
6 (7.14%) 44 (6.58%) 0.84 (chi2) 
*ttest ****Fisher’s exact 
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Tests suggestive of reproductive tract and Sexually transmitted disease. 
At least 15 mls of first catch urine was sent for PCR testing of Chlamydia, Gonorrhea and 
Trichomonas at every visit. The women were asked to not clean the vulva and not to urinate 
at least 2 hours prior to collection of the sample. Blood tests for HIV were performed at 
every visit. Tests for Syphilis were done at entry and exit. TPHA was only done in 215 women 
who were RPR positive (not included in this analysis- only 5 were positive). A test for Herpes 
was done at entry and only repeated at the end of the trial in those women who tested 
negative. There were no statistical differences in incident cervical abnormalities amongst 
women with objective evidence of a STI and no infection.    
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Table 13: A description and comparison of test results of STI's 
n=753 Abnormal Cytology 
n=84 (11.16%) 
Normal Cytology 
n= 669 (88.84%) 
 
p-value 
Chlamydia at entry 
n=41 (3.44%) 
5 (5.95%) 36 (5.38%) 0.84**** 
Chlamydia at repeat 
testing 
n=32 (4.25%) 
2 (2.38%) 30 (4.48%) 0.54****  
Gonorrhea at entry 
n=7 (0.93) 
1 (1.19%) 6 (0.90%) 0.57**** 
Gonorrhea at repeat 
testing 
n=13 (1.73%) 
2 (2.38%) 11 (1.64%) 0.52**** 
Trichomonas 
n=12 (1.59%) 
1 (1.19%) 11 (1.64%) 1**** 
Trichomonas on repeat 
testing 
n=38 (5.05) 
4 (4.76%) 34 (5.08%) 0.67**** 
Syphilis RPR at entry n=220 
(29.22%) 
20 (23.22%) 200 (29.90%) 0.39**** 
WR titre using <1/8 as 
negative and ≥ 1/8 as 
positive- n= 10 (4.55%) if 
RPR positive  
1 (5%) 9(4.5%) 1 **** 
RPR at exit 
n= 17 (2.26%) 
1 (1.19%) 16 (2.39%) 0.13**** 
HSV at entry 
482 (64.01%) 
56 (66.67%) 426 (63.68%) 0.81 (chi2) 
 
HSV was only repeated in 
those women where 
herpes was negative n=25 
(3.32%) 
3 (3.57%) 22 (3.29%) 0.84**** 
Pregnancy 
n=22 (2.92%) 
2 (2.38%) 20 (2.99%) 0.35**** 
HIV 
N=10 (1.33%) 
2 (2.38%) 8 (1.20%) 0.20**** 
****Fisher’s exact 
 
Univariate & Multivariate Analysis: 
Condoms compared to the diaphragm in this trial remained a significant factor in 
preventing incident cytological abnormalities. History of an ectopic pregnancy, vaginal 
discharge and every increase in the number of sexual partners were important risk factors. 
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The incidence of HIV was significantly associated with the outcome in the multivariate 
analysis. The multivariate analysis in Table 14 was using every variable (including those 
variable that were not significant in the Univariate analysis). Table 15 is the model only 
considering those factors that were significant in the Univariate analysis. 
Table 14: Univariate and Multivariate analysis 
 Univariate Analysis 
Odds Ratio (95%CI), p-value 
Multivariate Analysis 
Odds Ratio (95%CI), p-
value 
Age 0.98 (0.95-1.01), 0.17  0.97  (0.89- 1.05), 0.42     
Age more than 30 compared to under 
30 years 
0.84 (0.53-1.34), 0.46 1.81(0.56-5.83), 0.32      
Unmarried women compared to being 
married 
1.78 (0.94-3.36), 0.08 1.58(0.68-3.68), 0.29      
Number of Housemates 0.92 (0.83-1.03), 0.17 0.90 (0.78-1.04),0.14      
 
Contraception-Barrier: 
Have you used a male condom at the 
vaginal last sexual intercourse? 
0.70 (0.41-1.18), 0.18 0.75 (0.40-1.39), 0.36 
Ever used male condoms 0.90 (0.53-1.54), 0.70 1.34 (0.53-3.37), 0.53      
 
Condoms as compared to diaphragm 0.59 (0.37-0.94), 0.03 0.51  (0.27-0.97), 0.04      
Pregnancy History: 
Number of Vaginal births if pregnant 0.62 (0.38-1.01), 0.06 0.76 (0.38-1.52), 0.44      
History of ever having had an ectopic 
pregnancy 
3.31 (1.01-10.79), 0.05 9.25 (1.78-48.02), 0.01      
 
History of any poor pregnancy outcome 1.76 (0.88-3.52), 0.11 1.08 (0.38-3.06),0.89      
 
Sexual History: 
Coitarche at the age of 19 or less 
compared to older than 19 
0.52 (0.23-1.17), 0.11 0.83  0.32-2.14(0.70)      
 
Sex in exchange 2.52 (0.80-7.92), 0.11 3.60 (0.88-14.67),0.07      
 
Number of male partners 1.10 (1.03-1.18), 0.00 1.12 (1.03-1.22), 0.01 
 
Medical History: 
History of admission to hospital  1.83 (1.06-3.16), 0.03 1.50 (0.75-3.10), 0.25 
Sexually Transmitted Disease: 
History of having been treated for a 
Sexually transmitted disease 
1.46 (0.87-2.47), 0.15 0.98 (0.50- 1.90), 0.95      
Number of times treated 2.43 (1.21-4.89), 0.01 6.59 (1.54-28.19), 0.01 
History of symptoms suggestive of an 
STI compared to no such symptoms 
2.54 (1.36-4.75), 0.00 0.37 (0.04-3.51), 0.39 
History of Vaginal Discharge 3.74 (1.78-7.89), 0.00 13.95 (1.18-164.47), 0.04 
History of ongoing vaginal discharge 3.07 (0.80-11.81), 0.10 0.11 (0.00-3.84), 0.22 
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Any ongoing genital symptoms 2.29 (0.83-6.36), 0.11 4.47 (0.25-78.78), 0.53 
Vaginal ph> 4.5 as compared to <4.5 1.45 (0.91-2.33), 0.12 1.11 (0.53-3.37), 0.53 
RPR at exit 0.56 (0.07-4.26), 0.57  
HIV  2.08 (0.43-10.00), 0.36 6.58 (1.14-38.16), 0.04 
 
Model for predicting an abnormal Pap smear after a normal or inadequate Pap smear:  
Incident HIV infection was associated with 6 fold increase in the risk of an abnormal pap 
smear.  An abnormal discharge in the last 3 months increases the risk by 5 fold, and ever 
having had an ectopic pregnancy increases the risk 8 fold. Having used a condom after the 
last intercourse had no effect, but being allocated to the control (condom) arm reduced the 
risk by approximately 58%. The Model correctly classifies 89.88% of the abnormal Pap 
smears, with a low sensitivity of 9.38% and a specificity of 99.81%. There were no interaction 
issues in the model and model diagnostics were performed. The assumption of linearity on 
the logit scale was assessed for and ensured that it was not violated. The fit of the model was 
adjudged to be good by the Hosmer – Lemeshow goodness of fit test. 
Table 15: Logistic regression model with predictors for an abnormal Pap smear 
Predictor OR p-value (CI) 
HIV infection 6.26 0.04 (1.14-34.50) 
Ongoing abnormal vaginal 
discharge 
0.09 0.07 (0.01-1.26) 
Number of housemates 0.89 0.11 (0.78-1.03) 
Abnormal Discharge in the last 
3 months 
5.14 0.00 (1.79-14.78) 
Any ongoing genital symptoms 4.78 0.07 (0.89-25.78) 
Having been treated for a 
sexually transmitted disease? 
0.67  0.28 (0.32-1.39) 
Number of male partners 1.12 0.00 (1.04-1.21) 
History of ever having had an 
ectopic pregnancy 
8.70 0.00 (2.07-36.45) 
Sex in exchange for food, 
Herring or Money 
3.44 0.07 (0.90-13.11) 
Having had a Vaginal birth. 0.70 0.25 (0.38-1.28) 
Having used a male condom at 
last intercourse 
0.80 0.47 (0.44-1.47) 
Being randomized to the 0.42 0.01 (0.22-0.77) 
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condom arm rather than to the 
diaphragm arm 
 
Chapter 4: Discussion, limitations and Conclusions. 
Discussion: 
The aim of this study was to find the incidence of Pap smear abnormalities when the Pap 
smear was repeated between 1-2 years and it was found that there is a significantly higher 
incidence of cytological abnormalities in women where the Pap smear was reported as 
inadequate as compared to where the Pap smear was adequate (and otherwise normal). The 
incidence of any abnormality was 7.33% per year; however the incidence of a HSIL was low, 
0.46% and 0.37% in the inadequate versus the adequate group.   
Repeating the Pap smear within two years in SA may increase the cost without adding 
any significant increase in finding disease. Although there are no prospective studies that 
have directly compared screening intervals in any given population, there is information 
from eight screening programs evaluating screening intervals. Screening every 5, 3, 2 or 
annually was estimated to reduce the incidence of cancer by 84%, 91%, 93% and 94% 
respectively among women 35-64 years of age(68). The SA guidelines predict a reduction of 
cervical cancer by between 64%-70% with an interval of 10 year(8, 15). 
It is notable that the  National Health and medical Research Council Guidelines of 
Australia recommend that all pathologists  report normal Pap smear  with a recommendation 
that the next Pap smear is due in 2 years irrespective of the presence or absence of 
endocervical component or of reactive change(69).  
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One of the priorities for research set by the WHO consultative process was to evaluate 
the need for repeat pap smears by age(9).  In this study there was no difference in incidence 
with increased age. The median age was 28 and the odds of having an abnormal Pap smear 
was 1.80 (NS) for women older than 30years in the multivariate analysis. Sasieni et al showed 
that the protective effect of a negative pap is less in younger women (20-39 years) than in 
women aged 40 or older(4).  
71.57% of women reported that they had used condoms with their last intercourse.  The 
use of male condoms was protective against acquiring an abnormal Pap smear, but this was 
not statistically significant. Assignment to the condoms only arm was associated with a 50% 
less risk of an abnormal Pap smear than the diaphragm arm (p=0.01).  This was however for 
the duration of the study, long term studies with consistent condom use is necessary. 
Condom use has been previously shown to reduce HPV transmission(70), persistence(71) and 
seropositivity(57).  
A history of an ectopic pregnancy increased the risk of an abnormal Pap smear by 8 times 
as compared to women who have never had a Pap smear. This would suggest either long 
standing infection or some factor which allowed upper genital tract infection. Other variables 
which are indicative of Sexually transmitted disease were conflicting. A history of vaginal 
discharge in the last 3 months was associated with a 5 fold increased risk, whereas clinician 
detected infection, or objective tests for sexually transmitted disease showed no association.  
There was no testing for HPV in this group of women; if we use abnormal cytology as a 
proxy for HPV infection then the incidence of infection with this virus is much higher than the 
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other two. The incidence of Herpes was 3.32%, HIV 1.33% and HPV (using Abnormal Pap 
smears as a marker) was at least 7.33%.  HIV infection of 1.33% is much lower than in the 
parent study which was 4%(67). HPV infection was not shown to be a risk factor for HIV 
infection in the a Zimbabwean study, but because women with dysplasia on their entry Pap 
were excluded from this study it may be that dysplastic cervical epithelium may account for 
the higher HIV infection in the parent study. However we did not set out to examine the risk 
of HIV infection in this group of women - It is merely speculative at this time. The association  
between HIV and HPV is well known(72). However interventions such as circumcision which 
reduce the incidence HIV are also associated reduction in HPV related disease like cervical 
cancer(73).  
The model that was used to find predictors of abnormal Pap smears had a low sensitivity 
of 9.38%, but the interval of less than 2 years which was used in this study is probably too 
frequent.  
Limitations and strengths: 
The study population used in this study was chosen post randomization and this may lead 
to bias.  The study had limited power to determine the risk factors associated with an 
abnormal pap smear. 
All women with an STI detected in the study were treated, and those who refused to be 
treated were excluded. The participants in this study were asymptomatic and recruited to 
participate in this study. The results may be completely different in symptomatic women 
presenting at a Gynaecological clinic or in asymptomatic women with an STI. 
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Cancer of the cervix is a disease of women in the 5th decade and only 25% of this group of 
women were older than 35 (Median age=28 (iqr-22-35). The sample size was too small to 
stratify women into different age categories. Variables that are traditionally associated with 
cervical cancer like “smoking” were not explored(50). The effect of hormonal contraception 
is dependent on duration of use and women were not asked about length of use(54, 55).  
The  association  of HPV and cancer of the cervix , with an OR of more than 50(18, 19), 
makes this the most important predictor of cervical dysplasia and HPV testing was not 
performed. However in SA HPV testing is expensive and would not be clinically useful in the 
immediate future.  
Although Pap smear screening has a high specificity, only colposcopically directed 
biopsies can confirm the exact grade of the lesion. Women with cervical abnormalities were 
managed according to clinical protocols and the results of colposcopy and histology were not 
part of this study. 
 The strengths of the study is that the study population comprised sexually active women 
from Soweto, an area with a high prevalence of cervical cancer and the completeness of the 
data and the low loss to follow-up. 
Conclusions and Recommendations: 
The incidence of cervical abnormalities is high, and higher in women with unsatisfactory 
Pap smears than in women with satisfactory Pap smears. The incidence of HSIL is less than 
0,5% per annum.  The situation is complicated by the fact that most women will clear a 
LSIL(74, 75)  Repeat screening in women with a normal Pap smear with two years may 
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therefore increase the cost, increase the number of women referred to colposcopy services 
and increase levels of anxiety experienced by these women.   
The SA guidelines recommend repeat Pap smears when the cytology report states that 
the examination of the slide was unsatisfactory. This is important in a service where the 
screening interval is 10 years and where many women may only have one Pap smear in a life-
time. However this study suggests that it would be safe for the next Pap to be delayed for at 
least one year. 
The Increased odds of having an abnormal Pap smear in women with incident HIV 
infection is further evidence that women who are HIV infected have a Pap smear at the time 
of diagnosis of the HIV and more frequently than the general population. The increased 
association with Vaginal discharge, ectopic pregnancy, and increased number of sexual 
partners would also warrant more frequent testing.  
The ideal time of repeat testing cannot be determined, but further studies with increased 
numbers of women should be performed, and these should ideally be nested within a 
screening service at a primary health care level.  
Intervals of screening are only one aspect in the prevention program and increased 
coverage with as many women as possible being screened should still be a priority. 
The lower incidence of HIV infection in this sub-group of women in the MIRA trial does 
suggest that HPV or cervical dysplasia may increase the risk of HIV infection, so women with 
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a cervical cytological abnormality should be advised to use condoms and educated on safe 
sex. 
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Appendix 2: 
Permission to use Dataset at PHRU: 
Dear Yasmin, 
 Thank you for submitting a concept proposal to write a manuscript for MIRA. We received almost 30 
concepts from all sites and institutions involved in the study. A group of Investigators had the chance 
to discuss the concepts on April 18. 
 The primary MIRA manuscript, corresponding to the main HIV outcome, is targeted for submission to 
a journal by the end of May. Once the main paper is accepted for publication, analysis on other papers 
can begin. The priority for the second tier of papers is: papers pertaining to the secondary objectives of 
the study and Investigator-led papers. Currently we anticipate that analyses for these second tier 
papers will continue through August. Thereafter, analyses for the remaining papers may begin. 
 Copies of the MIRA dataset will be made available to each site after the main paper is accepted for 
publication. If you, or someone from your organization, has the capacity to do your own statistical 
analyses, this will assist you in getting your analysis completed sooner.  
 However, there is still progress that can be made now. Several concept proposals in fact do not 
require statistical help, or do not rely on the main, CIDEA dataset, and can proceed now. Several 
concept proposals require more detail, which should be developed in this interim period.  
 The specific feedback on your concept was as follows: 
 Your concept was approved.  
• Guy has indicated you should be able to complete this analysis in-house when the PHRU 
dataset is received (after the main paper is accepted).  
• Jennifer Tuveson at UCSF may have some data on PAPs at PHRU that you could begin 
looking at, as she monitored this closely during the trial.  
 Should you have any other questions, please feel free to write us back. 
 Sincerely, 
 Liz Montgomery & Heidi Fancher 
 on behalf of the MIRA Investigators 
 Liz Montgomery  
MIRA Protocol Director 
University of California, San Francisco 
50 Beale St., suite 1200 
San Francisco, CA 94105 
 ph(office): +1-415-597-4953 
ph (cell): +1-310-694-7212 
e mail: emontgomery@globalhealth.ucsf.edu 
  
 
 
 
                                                   
